As reported herein is the use of the bispecific antibody as reported herein in the manufacture of a medicament.

Another aspect as reported herein is use of the antibody as reported herein in the manufacture of a medicament for the treatment of Alzheimer's disease.

In one embodiment the medicament is for the treatment of amyloid disorders.

In one embodiment the medicament for the prevention and/or treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation. In one embodiment the disease is selected from the group consisting of dementia, Alzheimer's disease, motor neuropathy, Down's syndrome, Creutzfeldt Jacob disease, hereditary cerebral hemorrhage with amyloidosis Dutch type, Parkinson's

VL sequence as in SEQ ID NO: 21, including post-translational modifications of that sequence.

10. A pharmaceutical formulation comprising the antibody according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.

11. The antibody according to any one of claims 1 to 9 for use as a medicament.

12. The antibody according to any one of claims 1 to 9 for use in the treatment of Alzheimer's disease.

13. Use of the antibody according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of Alzheimer's disease.